Sobi® (STO: SOBI) today announced that data on Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune ...

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), ...

The trial tested two doses of claseprubart -- 300 mg and 600 mg -- and its primary endpoint was safety. Secondary outcomes included scores on the Myasthenia-Gravis Activities of Daily Living (MG-ADL) ...

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Dysregulated proteolysis is central to ...

The Chicago Bears had their best rushing outing in Sunday's win over the New Orleans Saints, where both D'Andre Swift and rookie Kyle Monangai had impressive showings. The Bears totaled 222 rushing ...

Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.

This study presents S-1117, an IgG-specific protease, as a promising therapeutic approach for the treatment of acetylcholine receptor-positive myasthenia gravis (AChR-MG). S-1117 was shown to ...